Gt Biopharma Inc SEC Filings

GT Biopharma director David C. Mun-Gavin acquired 31,250 shares of common stock by exercising options with a $1.33 exercise price. The reported transaction lists an acquisition of 31,250 option shares that convert to 31,250 common shares, and the filer notes the options are fully vested and exercisable.

The ownership after the reported transaction is 31,250 shares held directly. The filing is a standard Section 16 disclosure by an insider documenting option exercise and resulting beneficial ownership.

Michael Martin Breen, CEO and Director of GT Biopharma, reported three option grants on 09/04/2025 totaling 300,000 options to purchase common stock. Each option covers 100,000 shares with an exercise price of $1.33 and an expiration date of 08/19/2035. Following the reported transactions, Mr. Breen directly beneficially owns 100,000 shares for each grant (total reported underlying shares: 300,000). One grant is fully vested and exercisable; the other two vest in quarterly installments beginning 01/01/2025 and 01/01/2026 respectively. The form was signed on 09/08/2025.

Alan Urban, Chief Financial Officer of GT Biopharma, reported receipt of two stock option awards. Each option allows purchase of 50,000 shares of the company's common stock at an exercise price of $1.33 per share and lists 50,000 shares underlying each option. Both options expire on 08/19/2035. One option vests in four equal quarterly installments beginning on January 1, 2025; the other vests in four equal quarterly installments beginning on January 1, 2026. The filing reports the options as directly held by Mr. Urban and shows the reported post-transaction beneficial ownership as 50,000 shares per option line (totaling 100,000 underlying shares across both awards).

Charles J. Casamento, a director of GT Biopharma, acquired derivative securities tied to the company's common stock on 09/04/2025. The filing reports an acquisition of 62,500 options to purchase common stock with an exercise price of $1.33. The options are reported as fully vested and exercisable and are recorded as direct beneficial ownership of 62,500 underlying shares following the transaction. No cash price for the underlying shares is reported in the filing and no other transactions or dispositions are included.

Hilary Kramer, a director of GT Biopharma, Inc. (GTBP), exercised options to acquire 31,250 shares of common stock on 09/04/2025 at an exercise price of $1.33 per share. The options are reported as fully vested and exercisable, and following the transaction Ms. Kramer directly beneficially owns 31,250 shares. The Form 4 was signed by the reporting person and reflects a single option exercise converting derivative securities into common stock.